NCT06608758 End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
| NCT ID | NCT06608758 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rush University Medical Center |
| Condition | Disabilities Multiple |
| Study Type | OBSERVATIONAL |
| Enrollment | 120,000 participants |
| Start Date | 2024-11-22 |
| Primary Completion | 2029-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120,000 participants in total. It began in 2024-11-22 with a primary completion date of 2029-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People with disabilities (PWD) experience increased risk of diagnostic error-sometimes due to attributing symptoms to disability rather than a potentially new or co-morbid conditions. As well, some diagnoses are prone to error. Based on literature we identified the following twenty-six with ICD-10 codes: Aortic aneurysm and dissection I71.0 - I71.9; Arterial thromboembolism I74.0 - I74.9; Venous thromboembolism I82.0-I82.99 and I82.A-I82.C; Congestive heart failure I50.1-150.9; Stroke All I60, I61, I62, I63, I64; Myocardial infarction I21.0-I21.9 and I21.A-I21.B; Spinal abscess G06.0, G06.1 and G06.2; Meningitis and encephalitis G04 -G04.91; Endocarditis I33.0-I33.9 and I38; Sepsis A41.0-A41.9; Pneumonia J12.0-J95.851; Lung cancer C34.0-C34.92; Melanoma C43.0- C43.9; Colorectal cancer C18.0-C18.9; Breast cancer C50 to C50.929, and C79.81; Prostate cancer C61; Pediatric Arterial ischemic stroke I63.0-163.9xx; Appendicitis K35-K35.8xx; Asthma J45.2-J45.998; Retinal blastoma C69.20, C69.21, C60.22; Brain tumor C71.0-C71.9; Polyateritis M30.0-M30.8; Congenital heart disease Q20 - Q28 (Q24.9 particularly important); Duchense muscular dystrophy G71.0-G71.9; Inflammatory bowel disease K51.0-K51.9; Scleroderma M34.0-M34.9.The goal of this research is to identify and create understanding of what underlies and contributes to increased risk of diagnostic error with these diagnoses. The investigators plan to develop ways to reduce it, specifically ways to identify people with disabilities at risk of diagnostic error (DE). The investigators will also develop education programs and decision supports targeted to healthcare professionals. If it is effective, ways to reduce diagnostic error will have been developed among people with disabilities.
Eligibility Criteria
Inclusion Criteria: • Patients aged 3-89 who received billed charges Exclusion Criteria: * Patients under age 3 or over age 89. * Patients with secondary diagnosis of dementia as the population is already known to be at increased risk of diagnostic error
Contact & Investigator
Sarah H Ailey, PhD RN
PRINCIPAL INVESTIGATOR
Rush University College of Nursing
Frequently Asked Questions
Who can join the NCT06608758 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 89 Years, studying Disabilities Multiple. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06608758 currently recruiting?
Yes, NCT06608758 is actively recruiting participants. Contact the research team at Jennifer_Garcia@rush.edu for enrollment information.
Where is the NCT06608758 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06608758 clinical trial?
NCT06608758 is sponsored by Rush University Medical Center. The principal investigator is Sarah H Ailey, PhD RN at Rush University College of Nursing. The trial plans to enroll 120,000 participants.